David Dai
Stock Analyst at UBS
(2.04)
# 3,069
Out of 5,182 analysts
40
Total ratings
39.39%
Success rate
-2.73%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Downgrades: Neutral | $57 → $15 | $14.34 | +4.60% | 2 | Apr 15, 2026 | |
| ASML ASML Holding | Maintains: Outperform | $1,911 → $1,971 | $1,427.02 | +38.12% | 3 | Mar 26, 2026 | |
| JSPR Jasper Therapeutics | Assumes: Neutral | $1.5 | $0.93 | +61.24% | 1 | Mar 23, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $7 → $8 | $3.85 | +107.79% | 3 | Mar 18, 2026 | |
| SONY Sony Group | Downgrades: Market Perform | $30 → $22 | $19.78 | +11.22% | 2 | Mar 17, 2026 | |
| KURA Kura Oncology | Maintains: Buy | $16 → $15 | $8.77 | +71.04% | 4 | Mar 13, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $2 → $4 | $3.40 | +17.65% | 3 | Mar 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $90 → $128 | $80.71 | +58.59% | 1 | Mar 3, 2026 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $97.54 | +19.95% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $19.11 | +98.85% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $114 → $132 | $99.04 | +33.28% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $11.26 | +77.62% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $26 | $16.81 | +54.67% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $16.12 | +86.16% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $13.43 | +78.70% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $28.16 | -14.77% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $28.19 | +77.37% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $66.27 | -9.46% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $8.20 | +5,363.41% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $128.79 | -68.94% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.13 | +1,177.96% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.93 | +1,606.48% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.96 | +73.56% | 1 | Mar 17, 2020 |
Janux Therapeutics
Apr 15, 2026
Downgrades: Neutral
Price Target: $57 → $15
Current: $14.34
Upside: +4.60%
ASML Holding
Mar 26, 2026
Maintains: Outperform
Price Target: $1,911 → $1,971
Current: $1,427.02
Upside: +38.12%
Jasper Therapeutics
Mar 23, 2026
Assumes: Neutral
Price Target: $1.5
Current: $0.93
Upside: +61.24%
Perspective Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $7 → $8
Current: $3.85
Upside: +107.79%
Sony Group
Mar 17, 2026
Downgrades: Market Perform
Price Target: $30 → $22
Current: $19.78
Upside: +11.22%
Kura Oncology
Mar 13, 2026
Maintains: Buy
Price Target: $16 → $15
Current: $8.77
Upside: +71.04%
Iovance Biotherapeutics
Mar 5, 2026
Maintains: Neutral
Price Target: $2 → $4
Current: $3.40
Upside: +17.65%
Kymera Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $90 → $128
Current: $80.71
Upside: +58.59%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $97.54
Upside: +19.95%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $19.11
Upside: +98.85%
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $99.04
Upside: +33.28%
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $11.26
Upside: +77.62%
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $16.81
Upside: +54.67%
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $16.12
Upside: +86.16%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $13.43
Upside: +78.70%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $28.16
Upside: -14.77%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $28.19
Upside: +77.37%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $66.27
Upside: -9.46%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $8.20
Upside: +5,363.41%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $128.79
Upside: -68.94%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.13
Upside: +1,177.96%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.93
Upside: +1,606.48%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.96
Upside: +73.56%